Please ensure Javascript is enabled for purposes of website accessibility

A Brief History of Teva Pharmaceutical's Returns

By Motley Fool Staff – Updated Apr 6, 2017 at 5:03PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Understanding how you got from A to B.

Despite constant attempts by analysts and the media to complicate the basics of investing, there are only three ways a stock can create value for shareholders:

  1. Dividends.
  2. Earnings growth.
  3. Changes in valuation multiples.

In this series, we drill down on one company's returns to see how each of those three has played a role over the past decade. Step on up, Teva Pharmaceutical (Nasdaq: TEVA).

Teva shares returned 220% over the past decade. How'd they get there?

Dividends made up only a small portion. Without dividends, shares returned 194% over the last 10 years.

Earnings growth was substantial. Teva's normalized earnings per share grew at an average rate of 22% a year from 2001 until today -- easily among the upper echelon of large-cap companies over the last decade.

But think about that for a moment. Teva's earnings grew far faster than its shareholder returns. Earnings increased over sixfold, while shares a little more than doubled.

Why? This chart explains it:

Source: S&P Capital IQ.

Like so many large-cap companies -- particularly pharmaceuticals -- Teva was vastly overvalued a decade ago. Valuations have since contracted, preventing a lot of the company's earnings growth from turning into shareholder returns. The same has been true for larger rivals Pfizer (NYSE: PFE) and Merck (NYSE: MRK), both of which have seen shareholder returns wither as valuations come back to Earth.

The good news is that, at 15 times earnings, Teva shares now look reasonably valued. The past decade saw shareholder returns stifled due to falling multiples. The coming decade could see rising, even expanding multiples, allowing more of the company's earnings growth to turn into shareholder returns.

Why is this stuff worth paying attention to? It's important to know not only how much a stock has returned, but where those returns came from. Sometimes earnings grow, but the market isn't willing to pay as much for those earnings. Sometimes earnings fall, but the market bids shares higher anyway. Sometimes both earnings and earnings multiples stay flat, but a company generates returns through dividends. Sometimes everything works together, and returns surge. Sometimes nothing works and they crash. All tell a different story about the state of a company. Not knowing why something happened can be just as dangerous as not knowing that something happened at all.

Fool contributor Morgan Housel doesn't own shares in any of the companies mentioned in this article. Follow him on Twitter @TMFHousel. The Motley Fool owns shares of Teva Pharmaceutical Industries. Motley Fool newsletter services have recommended buying shares of Teva Pharmaceutical Industries and Pfizer. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Teva Pharmaceutical Industries Limited Stock Quote
Teva Pharmaceutical Industries Limited
TEVA
$7.69 (-2.66%) $0.21
Merck & Co., Inc. Stock Quote
Merck & Co., Inc.
MRK
$86.18 (-0.69%) $0.60
Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$43.83 (-0.57%) $0.25

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
329%
 
S&P 500 Returns
106%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.